| Document |
Document Title |
|
WO/2024/010039A1 |
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof. This ophthalmic composition has a pH of 4.0 to 6.8 and is stored in a container in which a portion of or all of the part thereof contacting...
|
|
WO/2024/010043A1 |
The present invention relates to an ophthalmic composition which contains tramadol or a salt thereof and does not substantially contain a preservative agent.
|
|
WO/2024/010040A1 |
The present invention relates to an ophthalmic composition containing tramadol or a salt thereof, and a biguanide-based preservative.
|
|
WO/2024/010896A1 |
The present invention is directed to methods for treating macular degeneration, atherosclerosis, fatty liver, obesity, and cognitive ability, and more specifically to methods for treating macular degeneration, atherosclerosis, fatty live...
|
|
WO/2024/010045A1 |
The present invention relates to a pain suppressant for the trigeminal nerve, the pain suppressant containing tramadol or a salt thereof.
|
|
WO/2024/008088A1 |
Disclosed are a class of compounds as TRK inhibitor drugs or RET inhibitor drugs and use thereof. Specifically, disclosed is use of a compound represented by formula (G), or an isotope-labeled compound thereof, or an optical isomer, a ge...
|
|
WO/2024/006916A1 |
Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.
|
|
WO/2024/005502A1 |
The present invention provides: an Hyal1 variant in which at least one amino acid adjacent to a catalytic amino acid in wild-type human hyaluronidase Hyal1 comprising aspartic acid and glutamic acid as catalytic amino acids is substitute...
|
|
WO/2024/001067A1 |
The present invention relates to a benzofuran compound or a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. The compound has a structural formula as shown in formula I, which has good solubili...
|
|
WO/2024/005627A1 |
The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of bioactive agents contained in peppermint leaf extract to the scleral tissue of the posterior segment of the...
|
|
WO/2024/005113A1 |
The present invention addresses the problem of providing a novel compound that has a thyroid-stimulating hormone receptor antagonist activity and is useful for the treatment of thyroid-related diseases.　The present invention relates to...
|
|
WO/2024/006248A1 |
The invention provides stable ophthalmic formulations, a unit dose containing such formulations, medical kits, and methods for making and using such formulations and unit doses to treat patients suffering from a disorder mediated by an Î...
|
|
WO/2024/002076A1 |
The present invention belongs to the technical field of recombinant adeno-associated virus (rAAV) gene therapy, relates to the preparation of an rAAV-delivered Fc-engineered VEGF receptor fusion protein or an anti-VEGF antibody, and is a...
|
|
WO/2024/001964A1 |
Provided are a nimodipine composition free of ethanol and phospholipid for moist heat sterilization and a method for preparing same. The composition comprises: (1) nimodipine; (2) a non-phospholipid surfactant selected from a mixture of ...
|
|
WO/2024/003578A1 |
The present invention provides a vector comprising a nucleotide sequence encoding an anti- TNF antibody or a fragment thereof, wherein the nucleotide sequence encoding the anti-TNF antibody or a fragment thereof is operably linked to an ...
|
|
WO/2022/266394A9 |
The present disclosure provides a compound having the structure : Formula (I) or Formula (II).
|
|
WO/2023/246854A1 |
The present disclosure relates to a crystal of a borate derivative, a method for preparing same, and use thereof. Specifically, the present disclosure provides a crystal of a compound represented by formula I, a method for preparing same...
|
|
WO/2023/249007A1 |
The present invention provides a calpain inhibitor that has excellent calpain inhibitive capacity. The present invention provides a compound represented by general formula (I), or a salt thereof. (In formula (I), R1 represents a hydrogen...
|
|
WO/2023/246827A1 |
The present invention relates to the technical field of biological medicines, and particularly, to a micromolecular drug-oligonucleotide conjugate and use thereof. The present invention solves the problems of poor water solubility and di...
|
|
WO/2023/250031A1 |
The present invention relates to pharmaceutical compositions of docosahexaenoic acid (DHA) analogs for treating hearing and ocular disorders.
|
|
WO/2023/250291A2 |
The present disclosure provides methods of treating corneal disorders with modulators of the WNT signalling pathway. More particularly, provided are treatments for cornea epithelial and/or endothelial injuries, defects, deficiencies, and...
|
|
WO/2023/249475A1 |
The present invention relates to a pharmaceutical composition for preventing or treating retinal diseases, comprising a CRISPR/Cas complex as an active ingredient. The present invention is research for developing a technology for targeti...
|
|
WO/2023/247774A1 |
The present disclosure relates to a novel treatment regimen for the treatment of autoimmune diseases and other inflammatory diseases with BTK (Bruton's tyrosine kinase) inhibitors. In particular, the present disclosure relates to a treat...
|
|
WO/2023/247712A1 |
The present invention relates to substituted 1,2,3-triazoles of formula (I) useful for the treatment of ocular diseases, in particular those related to retinal degeneration. The invention also relates to pharmaceutical compositions to tr...
|
|
WO/2023/240379A1 |
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, ste...
|
|
WO/2023/241697A1 |
The present disclosure provides a cell (e.g., AMD-associated cell, such as RPE) comprising a polypeptide capable of reversing phase separation and/or preventing the formation of drusen, a polynucleotide encoding the polypeptide, and/or a...
|
|
WO/2023/241652A1 |
The present invention provides a pharmaceutical composition, a method for preparing same, and use thereof. The pharmaceutical composition comprises a compound represented by formula I. The pharmaceutical composition of the present invent...
|
|
WO/2023/245131A1 |
The present disclosure provides compositions and vectors comprising a transgene(s) encoding more than one isoform of Crumbs homologue-1 (CRB1) (e.g., CRB1-A and CRB1-B), and compositions thereof, for use in the treatment or prevention of...
|
|
WO/2023/244618A1 |
A pharmaceutical composition for use in treating dry eye disease includes a peptide having the amino-acid sequence selected from SEQ ID NO: 1-7. The dry eye disease is accompanied with cataract. The subject suffers from cataract that has...
|
|
WO/2023/240958A1 |
The present invention relates to a use of a JWA polypeptide in preparation of a drug for resisting a neovascular ocular disease. The amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an am...
|
|
WO/2023/242331A1 |
The present invention relates to the treatment of corneal endothelial cells in corneal disease and/or dysfunction. Further, the present invention relates to a method of preparing corneal endothelial cells in vitro.
|
|
WO/2023/237012A1 |
Provided are a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/236485A1 |
Disclosed are artemisinin derivatives, a preparation method therefor, and the uses thereof. The structural formula of the artemisinin derivatives is represented by formula I. The compounds have suitable solubility and are relatively stab...
|
|
WO/2023/240062A1 |
Provided herein, inter alia, are melanopsin variants that demonstrate greater amplitude/conductance and/or faster off kinetics than the amplitude/conductance and/or the off kinetics of the wild type human melanopsin. Also provided are re...
|
|
WO/2023/237898A1 |
The present invention relates to novel pharmaceutical formulations. More specifically, the present invention relates to novel pharmaceutical formulations that are suitable for administration to the eye. The present invention also relates...
|
|
WO/2023/240155A1 |
Methods to treat dry eye disease and to slow, inhibit or delay progression of dry eye disease in a subject are provided. The methods comprise administering a composition comprising a therapeutically effective amount of a compound that in...
|
|
WO/2023/237733A1 |
The invention relates to the use of at least one molecule selected from among an annelid globin, an annelid globin protomer and an annelid extracellular hemoglobin for the treatment of Fuchs' disease.
|
|
WO/2023/240092A1 |
The present disclosure provides a pharmaceutical composition comprising ebselen, wherein the composition is formulated for oral administration. Also provided are pharmaceutical dosage forms including the same. In some embodiments, the do...
|
|
WO/2023/236964A1 |
Provided is a pharmaceutical composition, the pharmaceutical composition comprising a recombinant adeno-associated virus (AAV), a buffer solution, an amino acid, a stabilizer, and a nonionic surfactant. The pharmaceutical composition has...
|
|
WO/2023/237902A1 |
Formulations and methods of using mitochondrially targeted antioxidants (SkQ) to improve dry eye conditions in subjects having a tear production of ≥ 7 mm measured by a Schirmer's test are provided. The methods provide benefits to the ...
|
|
WO/2023/240094A1 |
The present disclosure provides an amorphous solid dispersion (ASD) comprising an amorphous form of ebselen. Also provided are pharmaceutical compositions and pharmaceutical dosage forms including the subject amorphous solid dispersion. ...
|
|
WO/2023/233994A1 |
The purpose of the present invention is to provide a pharmaceutical composition for treating or preventing diseases such as pulmonary diseases (excluding pulmonary fibrosis), renal diseases (excluding renal fibrosis), reproductive dysfun...
|
|
WO/2023/233570A1 |
The purpose of the present invention is to provide: a composition for treating acute rhinitis and allergic rhinitis; use of the same; and a method for treating acute rhinitis and allergic rhinitis. Specifically, the present invention per...
|
|
WO/2023/173093A9 |
This invention relates to continuous dosing of ocular drug delivery inserts in the eye of a subject to provide a desired amount of drug and/or desired rate of drug release for treatment of a condition of the eye. Release rates and drug a...
|
|
WO/2023/232022A1 |
The present application provides a recombinant fusion protein, comprising 1) a PD-L1 antibody or an antigen-binding fragment thereof, and 2) a VEGF-binding peptide, the N-terminus of a heavy chain or a light chain of the PD-L1 antibody o...
|
|
WO/2023/235433A1 |
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula (I). Also disclosed are methods of...
|
|
WO/2023/233169A1 |
In the proposed embodiment of the invention, is an ophthalmic patch resembling a contact lens, from which the central area is missing, comprising of various systems and devices that provide the following advantages: i) they are flexible ...
|
|
WO/2023/234703A1 |
The present invention provides a novel peptide derivative containing a specific D-amino acid and a pharmaceutical composition for preventing, ameliorating, or treating ophthalmic diseases comprising same. The peptide derivative of the pr...
|
|
WO/2023/234423A1 |
Provided herein are ophthalmic compositions comprising an effective amount of one or more rifamycin compounds or a pharmaceutically acceptable salt thereof, methods for preparing said compositions, and methods for use of said composition...
|
|
WO/2023/230657A1 |
The present invention relates to modified recombinant adeno-associated virus (AAV) capsid proteins and AAV particles thereof. In one aspect, the modified recombinant AAV particles provide for increased transduction of retinal cells when ...
|
